2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Women’s Health, Workforce, Adverse Events, Biological Processes, Apoptosis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3745 Long-term outcomes with vodobatinib in heavily pre-treated chronic Phase CML: Phase 1/2 study analysis

Jorge Cortes, MD, Dong-Wook Kim, MD, PhD2, Navin Khattry, MD DM3, Krishnakumar Rathnam, MD4, Yesid Alvarado Valero, MD5, Guy Hannah, MD6, Srinivas Tantravahi, MD7, Jane Felicity Apperley, FRCP, FRCPath, MB8, Aude Charbonnier, MD, PhD9, Valentín García Gutiérrez I, MD10, Alessandro Lucchesi, MD, PhD11, Delia Dima, MD12, Arpad Illes, MD13, Viola Maria Popov, MD14, Elisabetta Abruzzese, MD, PhD15, Arijit Nag, MD, DM16, Shashikant Sagar Apte, MD (Medicine), FRCPA17, Talha Badar, MD18, Nikki Granacher, MD19, Carlo Gambacorti-Passerini, MD20, Michael Mauro, MD21, Peter Vandenberghe, MD, PhD22, Andrew Whiteley, MD23, Marie Balsat, MD24, Rosa María Ayala Díaz, MD25, Guillermo Orti, MD26, Luminita Orcoteala, MD27, Siu-Long Yao, MD28, Sandeep Inamdar, MBBS29, Jayasree Sreenivasan, MSc30, Geetanjali Chandrashekhar Chimote, MBBS, PhD31, Franck Emmanuel Nicolini, MD, PhD32
1 University of Alabama at Birmingham,, Birmingham, United States
2 Uijeongbu Eulji Medical Center, Uijeongbu, Korea, Rep. of South
3 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Mumbai, India
4 Meenakshi Mission Hospital and Research Centre, Madurai, India
5 The University of Texas MD Anderson Cancer Center, Houston, United States
6 King’s College Hospital, NHS Foundation Trust, London, United Kingdom
7 Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
8 Imperial College London, London, United States
9 Institut Paoli-Calmettes Cancer Institute, Marseille, France
10 Hospital Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá, Madrid, Spain
11 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy
12 Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania
13 University of Debrecen, Debrecen, Hungary
14 Colentina Clinical Hospital, Bucharest, Romania
15 Sant’Eugenio Hospital, Tor Vergata University, Rome, Italy
16 Tata Medical Center, Kolkata, India
17 Sahyadri Specialty Hospitals, Pune, India
18 Mayo Clinic, Jacksonville, United States
19 Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
20 University of Milano-Bicocca, Monza, Italy
21 Memorial Sloan Kettering Cancer Center, New York, United States
22 University Hospital Leuven, Leuven, Belgium
23 Baylor University Medical Centre, Dallas, United States
24 CH Lyon Sud, Pierre Bénite, France
25 Hospital Universitario 12 de Octubre, Complutense University of Madrid, Madrid, Spain
26 Hospital Universitari Vall d'Hebron, Barcelona, Spain
27 Spitalul Clinic Municipal Filantropia, Craiova, Romania
28 Astera Cancer Care and Rutgers Robert Wood Johnson Medical School, East Brunswick, United States
29 Sun Pharma Advanced Research Company, Mumbai, India
30 Sun Pharma Advanced Research Company, Mumbai, India
31 Sun Pharmaceutical Industries, Inc., Princeton, United States
32 Centre Leon Berard, Lyon, France

Background: Vodobatinib is a potent and selective BCR::ABL1 tyrosine kinase inhibitor (TKI) active against wild-type BCR::ABL1 and its mutations (except T315I). CP-CML pts who have exhausted TKIs have an unmet need. We report long-term efficacy and safety outcomes of vodobatinib in heavily pre-treated CP-CML, including pts with baseline BCR::ABL1 mutations (NCT02629692).

Methods: Pts received once-daily vodobatinib (12–240 mg) in 28-day cycles. Primary endpoints were cytogenetic response and MTD; secondary endpoints were molecular responses, PFS, and OS. Molecular responses and BCR::ABL1 mutations were assessed centrally. AEs were graded per NCI CTCAE v4.03 (Phase 1) and v5.0 (Phase 2). Analyses included all treated pts. The study closed on 3 Jan 2025, for administrative reasons unrelated to safety.

Results: From Apr 2017 to Jan 2025, 69 pts with CP-CML received ≥1 dose of vodobatinib. Median age was 58 y (range 23–84); 37% male. Prior therapy included: ≥3 TKIs in 54 pts (78.2%), ponatinib in 39 (56.5%), ponatinib+asciminib in 8 (11.6%). Median study duration and follow-up were 30.9 mo (0.5-92.2) and 40.8 mo (0.7-92.2). At final assessment, 37 pts (53.6%) were in response; 26 transitioned to post-trial vodobatinib access and 11 to alternative therapies. The other 32 discontinued due to disease progression (12 [17.4%]), AEs (9 [13.0%]), death (1 [1.4%]), and other (10 [14.5%]).

At baseline, 12 pts (17.4%) were in CCyR and maintained them; 4 (5.7%) in MMR and all maintained them. Among evaluable pts (57 for CCyR; 64 for molecular response, excluding 1 atypical transcript), new responses included CCyR in 31 (54.4%), MMR in 27 (42.2%), and ≥MR4.0 in 17 (26.6%). Responses were durable over time. K-M estimates (90% CIs) showed that 88.0% (67.1%, 96.0%) maintained MMR ≥3 y, while 76.4% (44.2%, 91.9%) and 49.5% (19.5%, 73.8%) maintained ≥MR4.0 for ≥1 and ≥2 y respectively. At doses ≥174 mg (n=49), MMR and ≥MR4.0 were 21 (42.9%) and 13 (26.5%). K-M estimates (95% CIs) of 3-y OS and PFS were 88.7% (76.2%, 94.9%) and 73.3% (59.3%, 83.2%) respectively. Among 39 pts with prior ponatinib, MMR and ≥MR4.0 were 17 (43.6%) and 10 (25.6%): ponatinib-intolerant (n=24; MMR 13 [54.2%], ≥MR4.0 6 [25.0%]) and ponatinib-resistant pts (n=15; MMR 4 [26.7%], ≥MR4.0 4 [26.7%]). Among pts with prior ponatinib+asciminib (n=8), CCyR and MMR were observed in 3 (37.5%) and 2 (25.0%) pts.

Baseline BCR::ABL1 mutations were present in 22 pts (31.9%; most common F317L, G250E, V299L [n=2 each]). MMR and ≥MR4.0 were 7 (31.8%) and 4 (18.2%) in mutation-positive vs 20 (47.6%) and 13 (30.9%) in mutation-negative pts. Estimated 3-y OS and PFS were 77.1% (48.5, 91.1) and 42.6% (22.6, 67.0) in mutation-positive; and 93.9% (77.7, 98.5) and 86.6% (70.6, 94.2) in mutation-negative population. Median duration on study was 17.7 mo (0.6–75.4) in mutation-positive and 34.1 mo (3.0–92.2), in mutation-negative respectively.

Most common TEAEs (≥15%, any grade) were thrombocytopenia (31.8%), diarrhea (23.2%), constipation (21.7%), fatigue and cough (18.8% each), rash (17.4%), and nasopharyngitis (15.9%). Over 18 additional mo beyond the initial report (Lancet Haematol 2025), 115 TEAEs occurred in 23 pts, most frequently cough and rash (5.7% each). Most TEAEs occurred in the first year; new-onset hematologic AEs thereafter were uncommon (≤8%). Most common Grade 3/4 TEAEs were thrombocytopenia (13.0%), neutropenia (7.2%), anemia, and amylase increased (5.7% each). Six deaths occurred: 5 treatment-unrelated and 1 related intracranial hemorrhage, confounded by CNS blast phase with severe leukocytosis (390×10⁹/L).

Arterial occlusive events (AOEs) occurred in 10 pts (14.5%), including 3 beyond the initial report (Lancet Haematol 2025): Grade 2 ischemic stroke, coronary artery stenosis, and Grade 3 acute myocardial infarction (n=1 each). All 10 had cardiovascular comorbidities; 6 had prior ponatinib (1 with a prior ponatinib-associated AOE). Median time to AOE was 25.1 mo (range 0.4–70.8). Angina pectoris and CVA were the only AOEs occurring in >1 pt (n=2 each). All AOEs were unrelated to vodobatinib except 1 Grade 2 CVA; 1 fatal intracranial hemorrhage (above).

Conclusions: Vodobatinib demonstrated durable, deep responses with a manageable long-term safety profile in heavily treated CP-CML, including pts with ponatinib resistance/intolerance and baseline BCR::ABL1 mutations supporting further clinical development.

Jorge Cortes, MD: Bio-Path Holdings - Current holder of stock options in a privately-held company; Novartis - Honoraria; Takeda - Honoraria; Pfizer - Honoraria; Sun Pharma - Research Funding; Daiichi Sankyo - Research Funding; Novartis - Research Funding; Pfizer - Research Funding; Bio-Path Holdings - Consultancy (Includes expert testimony); Forma Therapeutics - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)